BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen F, Tzarum N, Wilson IA, Law M. VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design. Curr Opin Virol 2019;34:149-59. [PMID: 30884330 DOI: 10.1016/j.coviro.2019.02.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhu X, Yu F, Wu Y, Ying T. Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy. Antib Ther 2021;4:89-98. [PMID: 34104872 DOI: 10.1093/abt/tbab008] [Reference Citation Analysis]
2 Stewart V, Ronald PC. Sulfotyrosine residues: interaction specificity determinants for extracellular protein-protein interactions. Journal of Biological Chemistry 2022. [DOI: 10.1016/j.jbc.2022.102232] [Reference Citation Analysis]
3 Scheid JF, Barnes CO, Eraslan B, Hudak A, Keeffe JR, Cosimi LA, Brown EM, Muecksch F, Weisblum Y, Zhang S, Delorey T, Woolley AE, Ghantous F, Park SM, Phillips D, Tusi B, Huey-Tubman KE, Cohen AA, Gnanapragasam PNP, Rzasa K, Hatziioanno T, Durney MA, Gu X, Tada T, Landau NR, West AP Jr, Rozenblatt-Rosen O, Seaman MS, Baden LR, Graham DB, Deguine J, Bieniasz PD, Regev A, Hung D, Bjorkman PJ, Xavier RJ. B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell 2021;184:3205-3221.e24. [PMID: 34015271 DOI: 10.1016/j.cell.2021.04.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Lin YR, Parks KR, Weidle C, Naidu AS, Khechaduri A, Riker AO, Takushi B, Chun JH, Borst AJ, Veesler D, Stuart A, Agrawal P, Gray M, Pancera M, Huang PS, Stamatatos L. HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors. Immunity 2020;53:840-851.e6. [PMID: 33053332 DOI: 10.1016/j.immuni.2020.09.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
5 Tong P, Gautam A, Windsor IW, Travers M, Chen Y, Garcia N, Whiteman NB, McKay LGA, Storm N, Malsick LE, Honko AN, Lelis FJN, Habibi S, Jenni S, Cai Y, Rennick LJ, Duprex WP, McCarthy KR, Lavine CL, Zuo T, Lin J, Zuiani A, Feldman J, MacDonald EA, Hauser BM, Griffths A, Seaman MS, Schmidt AG, Chen B, Neuberg D, Bajic G, Harrison SC, Wesemann DR. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell 2021:S0092-8674(21)00884-9. [PMID: 34332650 DOI: 10.1016/j.cell.2021.07.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
6 Biswas M, Yamazaki T, Chiba J, Akashi-Takamura S. Broadly Neutralizing Antibodies for Influenza: Passive Immunotherapy and Intranasal Vaccination. Vaccines (Basel) 2020;8:E424. [PMID: 32751206 DOI: 10.3390/vaccines8030424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Durham ND, Agrawal A, Waltari E, Croote D, Zanini F, Fouch M, Davidson E, Smith O, Carabajal E, Pak JE, Doranz BJ, Robinson M, Sanz AM, Albornoz LL, Rosso F, Einav S, Quake SR, McCutcheon KM, Goo L. Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics. Elife 2019;8:e52384. [PMID: 31820734 DOI: 10.7554/eLife.52384] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
8 Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Wang Z, C Lorenzi JC, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Da Silva J, Poston D, Finkin S, Cho A, Cipolla M, Oliveira TY, Millard KG, Ramos V, Gazumyan A, Rutkowska M, Caskey M, Nussenzweig MC, Bjorkman PJ, Hatziioannou T, Bieniasz PD. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity 2021;54:1853-1868.e7. [PMID: 34331873 DOI: 10.1016/j.immuni.2021.07.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
9 [DOI: 10.1101/2020.07.16.20153437] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Chen F, Tzarum N, Lin X, Giang E, Velázquez-Moctezuma R, Augestad EH, Nagy K, He L, Hernandez M, Fouch ME, Grinyó A, Chavez D, Doranz BJ, Prentoe J, Stanfield RL, Lanford R, Bukh J, Wilson IA, Zhu J, Law M. Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins. Immunity 2021;54:781-796.e4. [PMID: 33675683 DOI: 10.1016/j.immuni.2021.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
11 Yan Q, He P, Huang X, Luo K, Zhang Y, Yi H, Wang Q, Li F, Hou R, Fan X, Li P, Liu X, Liang H, Deng Y, Chen Z, Chen Y, Mo X, Feng L, Xiong X, Li S, Han J, Qu L, Niu X, Chen L. Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients. Emerg Microbes Infect 2021;10:1097-111. [PMID: 33944697 DOI: 10.1080/22221751.2021.1925594] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Prabhu PR, Carter JJ, Galloway DA. B Cell Responses upon Human Papillomavirus (HPV) Infection and Vaccination. Vaccines 2022;10:837. [DOI: 10.3390/vaccines10060837] [Reference Citation Analysis]
13 Claireaux M, Caniels TG, de Gast M, Han J, Guerra D, Kerster G, van Schaik BDC, Jongejan A, Schriek AI, Grobben M, Brouwer PJM, van der Straten K, Aldon Y, Capella-Pujol J, Snitselaar JL, Olijhoek W, Aartse A, Brinkkemper M, Bontjer I, Burger JA, Poniman M, Bijl TPL, Torres JL, Copps J, Martin IC, de Taeye SW, de Bree GJ, Ward AB, Sliepen K, van Kampen AHC, Moerland PD, Sanders RW, van Gils MJ. A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike. Nat Commun 2022;13:4539. [PMID: 35927266 DOI: 10.1038/s41467-022-32232-0] [Reference Citation Analysis]
14 Clemens E, Angeletti D, Holbrook BC, Kanekiyo M, Jorgensen MJ, Graham BS, Yewdell J, Alexander-Miller MA. Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem. JCI Insight 2020;5:135449. [PMID: 32078584 DOI: 10.1172/jci.insight.135449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Unterman A, Sumida TS, Nouri N, Yan X, Zhao AY, Gasque V, Schupp JC, Asashima H, Liu Y, Cosme C Jr, Deng W, Chen M, Raredon MSB, Hoehn KB, Wang G, Wang Z, DeIuliis G, Ravindra NG, Li N, Castaldi C, Wong P, Fournier J, Bermejo S, Sharma L, Casanovas-Massana A, Vogels CBF, Wyllie AL, Grubaugh ND, Melillo A, Meng H, Stein Y, Minasyan M, Mohanty S, Ruff WE, Cohen I, Raddassi K, Niklason LE, Ko AI, Montgomery RR, Farhadian SF, Iwasaki A, Shaw AC, van Dijk D, Zhao H, Kleinstein SH, Hafler DA, Kaminski N, Dela Cruz CS; Yale IMPACT Research Team. Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. Nat Commun 2022;13:440. [PMID: 35064122 DOI: 10.1038/s41467-021-27716-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
16 Zhang H, Chen P, Ma H, Woińska M, Liu D, Cooper DR, Peng G, Peng Y, Deng L, Minor W, Zheng H. virusMED: an atlas of hotspots of viral proteins. IUCrJ 2021;8. [PMID: 34614039 DOI: 10.1107/S2052252521009076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Strohl WR, Ku Z, An Z, Carroll SF, Keyt BA, Strohl LM. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs 2022. [PMID: 35476216 DOI: 10.1007/s40259-022-00529-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
18 Brasher NA, Adhikari A, Lloyd AR, Tedla N, Bull RA. Hepatitis C Virus Epitope Immunodominance and B Cell Repertoire Diversity. Viruses 2021;13:983. [PMID: 34070572 DOI: 10.3390/v13060983] [Reference Citation Analysis]
19 Tzarum N, Giang E, Kadam RU, Chen F, Nagy K, Augestad EH, Velázquez-Moctezuma R, Keck ZY, Hua Y, Stanfield RL, Dreux M, Prentoe J, Foung SKH, Bukh J, Wilson IA, Law M. An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. Sci Adv 2020;6:eabb5642. [PMID: 32754640 DOI: 10.1126/sciadv.abb5642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
20 Rouers A, Appanna R, Chevrier M, Lum J, Lau MC, Tan L, Loy T, Tay A, Sethi R, Sathiakumar D, Kaur K, Böhme J, Leo YS, Renia L, Howland SW, Singhal A, Chen J, Fink K. CD27hiCD38hi plasmablasts are activated B cells of mixed origin with distinct function. iScience 2021;24:102482. [PMID: 34113823 DOI: 10.1016/j.isci.2021.102482] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Zhou X, Ma F, Xie J, Yuan M, Li Y, Shaabani N, Zhao F, Huang D, Wu NC, Lee CD, Liu H, Li J, Chen Z, Hong Y, Liu WH, Xiao N, Burton DR, Tu H, Li H, Chen X, Teijaro JR, Wilson IA, Xiao C, Huang Z. Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. Cell Rep 2021;35:109109. [PMID: 33932326 DOI: 10.1016/j.celrep.2021.109109] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Pan Y, Du J, Liu J, Wu H, Gui F, Zhang N, Deng X, Song G, Li Y, Lu J, Wu X, Zhan S, Jing Z, Wang J, Yang Y, Liu J, Chen Y, Chen Q, Zhang H, Hu H, Duan K, Wang M, Wang Q, Yang X. Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries. Cell Discov 2021;7:57. [PMID: 34315862 DOI: 10.1038/s41421-021-00295-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Duncan JD, Urbanowicz RA, Tarr AW, Ball JK. Hepatitis C Virus Vaccine: Challenges and Prospects. Vaccines (Basel) 2020;8:E90. [PMID: 32079254 DOI: 10.3390/vaccines8010090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
24 Bonsignori M, Marcotrigiano J. HCV neutralization goes elite. Immunity 2022;55:195-7. [PMID: 35139349 DOI: 10.1016/j.immuni.2022.01.010] [Reference Citation Analysis]
25 Weber T, Potthoff J, Bizu S, Labuhn M, Dold L, Schoofs T, Horning M, Ercanoglu MS, Kreer C, Gieselmann L, Vanshylla K, Langhans B, Janicki H, Ströh LJ, Knops E, Nierhoff D, Spengler U, Kaiser R, Bjorkman PJ, Krey T, Bankwitz D, Pfeifer N, Pietschmann T, Flyak AI, Klein F. Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. Immunity 2021:S1074-7613(21)00536-7. [PMID: 34990590 DOI: 10.1016/j.immuni.2021.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
26 Murin CD, Gilchuk P, Ilinykh PA, Huang K, Kuzmina N, Shen X, Bruhn JF, Bryan AL, Davidson E, Doranz BJ, Williamson LE, Copps J, Alkutkar T, Flyak AI, Bukreyev A, Crowe JE Jr, Ward AB. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. Cell Rep 2021;35:108984. [PMID: 33852862 DOI: 10.1016/j.celrep.2021.108984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Shih HP, Ding JY, Sotolongo Bellón J, Lo YF, Chung PH, Ting HT, Peng JJ, Wu TY, Lin CH, Lo CC, Lin YN, Yeh CF, Chen JB, Wu TS, Liu YM, Kuo CY, Wang SY, Tu KH, Ng CY, Lei WT, Tsai YH, Chen JH, Chuang YT, Huang JY, Rey FA, Chen HK, Chang TW, Piehler J, Chi CY, Ku CL. Pathogenic autoantibodies to IFN-γ act through the impedance of receptor assembly and Fc-mediated response. J Exp Med 2022;219:e20212126. [PMID: 35833912 DOI: 10.1084/jem.20212126] [Reference Citation Analysis]
28 Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Lorenzi JCC, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Wang Z, Da Silva J, Poston D, Finkin S, Cho A, Cipolla M, Oliveira TY, Millard KG, Ramos V, Gazumyan A, Rutkowska M, Caskey M, Nussenzweig MC, Bjorkman PJ, Hatziioannou T, Bieniasz PD. Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. bioRxiv 2021:2021. [PMID: 33758864 DOI: 10.1101/2021.03.07.434227] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 17.0] [Reference Citation Analysis]
29 Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, Torres JL, Okba NMA, Claireaux M, Kerster G, Bentlage AEH, van Haaren MM, Guerra D, Burger JA, Schermer EE, Verheul KD, van der Velde N, van der Kooi A, van Schooten J, van Breemen MJ, Bijl TPL, Sliepen K, Aartse A, Derking R, Bontjer I, Kootstra NA, Wiersinga WJ, Vidarsson G, Haagmans BL, Ward AB, de Bree GJ, Sanders RW, van Gils MJ. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 2020;369:643-50. [PMID: 32540902 DOI: 10.1126/science.abc5902] [Cited by in Crossref: 500] [Cited by in F6Publishing: 490] [Article Influence: 250.0] [Reference Citation Analysis]
30 Salinas E, Boisvert M, Upadhyay AA, Bédard N, Nelson SA, Bruneau J, Derdeyn CA, Marcotrigiano J, Evans MJ, Bosinger SE, Shoukry NH, Grakoui A. Early T follicular helper cell activity accelerates hepatitis C virus-specific B cell expansion. J Clin Invest 2021;131:140590. [PMID: 33463551 DOI: 10.1172/JCI140590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
31 Flyak AI, Ruiz SE, Salas J, Rho S, Bailey JR, Bjorkman PJ. An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein. Elife 2020;9:e53169. [PMID: 32125272 DOI: 10.7554/eLife.53169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
32 Kumar S, Ju B, Shapero B, Lin X, Ren L, Zhang L, Li D, Zhou Z, Feng Y, Sou C, Mann CJ, Hao Y, Sarkar A, Hou J, Nunnally C, Hong K, Wang S, Ge X, Su B, Landais E, Sok D, Zwick MB, He L, Zhu J, Wilson IA, Shao Y. A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite. Sci Adv 2020;6:eabb1328. [PMID: 32938661 DOI: 10.1126/sciadv.abb1328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
33 Dugan HL, Stamper CT, Li L, Changrob S, Asby NW, Halfmann PJ, Zheng NY, Huang M, Shaw DG, Cobb MS, Erickson SA, Guthmiller JJ, Stovicek O, Wang J, Winkler ES, Madariaga ML, Shanmugarajah K, Jansen MO, Amanat F, Stewart I, Utset HA, Huang J, Nelson CA, Dai YN, Hall PD, Jedrzejczak RP, Joachimiak A, Krammer F, Diamond MS, Fremont DH, Kawaoka Y, Wilson PC. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity 2021;54:1290-1303.e7. [PMID: 34022127 DOI: 10.1016/j.immuni.2021.05.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
34 Walker LM, Shiakolas AR, Venkat R, Liu ZA, Wall S, Raju N, Pilewski KA, Setliff I, Murji AA, Gillespie R, Makoah NA, Kanekiyo M, Connors M, Morris L, Georgiev IS. High-Throughput B Cell Epitope Determination by Next-Generation Sequencing. Front Immunol 2022;13:855772. [PMID: 35401559 DOI: 10.3389/fimmu.2022.855772] [Reference Citation Analysis]
35 Hehle V, Beretta M, Bourgine M, Ait-Goughoulte M, Planchais C, Morisse S, Vesin B, Lorin V, Hieu T, Stauffer A, Fiquet O, Dimitrov JD, Michel ML, Ungeheuer MN, Sureau C, Pol S, Di Santo JP, Strick-Marchand H, Pelletier N, Mouquet H. Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers. J Exp Med 2020;217:e20200840. [PMID: 32579155 DOI: 10.1084/jem.20200840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
36 Chen F, Nagy K, Chavez D, Willis S, McBride R, Giang E, Honda A, Bukh J, Ordoukhanian P, Zhu J, Frey S, Lanford R, Law M. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development. Gastroenterology 2020;158:1058-1071.e6. [PMID: 31809725 DOI: 10.1053/j.gastro.2019.11.282] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
37 Chan KW, Luo CC, Lu H, Wu X, Kong XP. A site of vulnerability at V3 crown defined by HIV-1 bNAb M4008_N1. Nat Commun 2021;12:6464. [PMID: 34753944 DOI: 10.1038/s41467-021-26846-z] [Reference Citation Analysis]
38 [DOI: 10.1101/2020.05.12.088716] [Cited by in Crossref: 43] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
39 Clemens EA, Alexander-Miller MA. Understanding Antibody Responses in Early Life: Baby Steps towards Developing an Effective Influenza Vaccine. Viruses 2021;13:1392. [PMID: 34372597 DOI: 10.3390/v13071392] [Reference Citation Analysis]
40 Wang C, van Haperen R, Gutiérrez-Álvarez J, Li W, Okba NMA, Albulescu I, Widjaja I, van Dieren B, Fernandez-Delgado R, Sola I, Hurdiss DL, Daramola O, Grosveld F, van Kuppeveld FJM, Haagmans BL, Enjuanes L, Drabek D, Bosch BJ. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nat Commun 2021;12:1715. [PMID: 33731724 DOI: 10.1038/s41467-021-21968-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
41 Wang Q, Finzi A, Sodroski J. The Conformational States of the HIV-1 Envelope Glycoproteins. Trends Microbiol 2020;28:655-67. [PMID: 32418859 DOI: 10.1016/j.tim.2020.03.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 14.5] [Reference Citation Analysis]
42 Granai M, Amato T, Di Napoli A, Santi R, Vergoni F, Di Stefano G, Mancini V, Kovalchuk S, Cencini E, Carta AG, Aversa S, Ziepert M, Cevenini G, Lazzi S, Leoncini L, Bellan C. IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications. Virchows Arch 2020;477:143-50. [PMID: 31802229 DOI: 10.1007/s00428-019-02712-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
43 Khamassi M, Xu L, Rey J, Duchemin M, Bouceba T, Tuffery P, Tudor D, Bomsel M. The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals. PLoS Pathog 2020;16:e1009103. [PMID: 33315937 DOI: 10.1371/journal.ppat.1009103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Boughter CT, Borowska MT, Guthmiller JJ, Bendelac A, Wilson PC, Roux B, Adams EJ. Biochemical patterns of antibody polyreactivity revealed through a bioinformatics-based analysis of CDR loops. Elife 2020;9:e61393. [PMID: 33169668 DOI: 10.7554/eLife.61393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Agudelo M, Palus M, Keeffe JR, Bianchini F, Svoboda P, Salát J, Peace A, Gazumyan A, Cipolla M, Kapoor T, Guidetti F, Yao KH, Elsterová J, Teislerová D, Chrdle A, Hönig V, Oliveira T, West AP, Lee YE, Rice CM, MacDonald MR, Bjorkman PJ, Růžek D, Robbiani DF, Nussenzweig MC. Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. J Exp Med 2021;218:e20210236. [PMID: 33831141 DOI: 10.1084/jem.20210236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
46 Bennett MR, Dong J, Bombardi RG, Soto C, Parrington HM, Nargi RS, Schoeder CT, Nagel MB, Schey KL, Meiler J, Skaar EP, Crowe JE Jr. Human VH1-69 Gene-Encoded Human Monoclonal Antibodies against Staphylococcus aureus IsdB Use at Least Three Distinct Modes of Binding To Inhibit Bacterial Growth and Pathogenesis. mBio 2019;10:e02473-19. [PMID: 31641091 DOI: 10.1128/mBio.02473-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
47 van der Weele L, Pollastro S, van Schaik BDC, van Kampen AHC, Niewold ITG, Kuijpers TW, Warnke C, Jensen PEH, Kramer D, Ryner M, Hermanrud C, Dönnes P, Pallardy M, Spindeldreher S, Deisenhammer F, Fogdell-Hahn A, de Vries N; ABIRISK Consortium. Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis. J Neuroimmunol 2022;370:577932. [PMID: 35853357 DOI: 10.1016/j.jneuroim.2022.577932] [Reference Citation Analysis]
48 Miller NL, Raman R, Clark T, Sasisekharan R. Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies. Front Immunol 2022;13:904609. [DOI: 10.3389/fimmu.2022.904609] [Reference Citation Analysis]
49 Yechezkel I, Law M, Tzarum N. From Structural Studies to HCV Vaccine Design. Viruses 2021;13:833. [PMID: 34064532 DOI: 10.3390/v13050833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Sepulveda-Crespo D, Resino S, Martinez I. Hepatitis C virus vaccine design: focus on the humoral immune response. J Biomed Sci 2020;27:78. [PMID: 32631318 DOI: 10.1186/s12929-020-00669-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
51 Mendoza-salazar I, Gómez-castellano KM, González-gonzález E, Gamboa-suasnavart R, Rodríguez-luna SD, Santiago-casas G, Cortés-paniagua MI, Pérez-tapia SM, Almagro JC. Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library. Antibodies 2022;11:13. [DOI: 10.3390/antib11010013] [Reference Citation Analysis]
52 Tong P, Gautam A, Windsor I, Travers M, Chen Y, Garcia N, Whiteman NB, McKay LGA, Lelis FJN, Habibi S, Cai Y, Rennick LJ, Duprex WP, McCarthy KR, Lavine CL, Zuo T, Lin J, Zuiani A, Feldman J, MacDonald EA, Hauser BM, Griffths A, Seaman MS, Schmidt AG, Chen B, Neuberg D, Bajic G, Harrison SC, Wesemann DR. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. bioRxiv 2021:2021. [PMID: 33758863 DOI: 10.1101/2021.03.10.434840] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 He L, Tzarum N, Lin X, Shapero B, Sou C, Mann CJ, Stano A, Zhang L, Nagy K, Giang E, Law M, Wilson IA, Zhu J. Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines. Sci Adv 2020;6:eaaz6225. [PMID: 32494617 DOI: 10.1126/sciadv.aaz6225] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
54 Law M. Antibody Responses in Hepatitis C Infection. Cold Spring Harb Perspect Med 2021;11:a036962. [PMID: 32341067 DOI: 10.1101/cshperspect.a036962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]